Paolo Simioni, MD, PhD; Paolo Prandoni, MD, PhD; Antonio Girolami, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Simioni P., Prandoni P., Girolami A.; Low Rate of Venous Thromboembolism in Asymptomatic Relatives of Probands with Factor V Leiden Mutation. Ann Intern Med. 1999;130:538. doi: 10.7326/0003-4819-130-6-199903160-00012
Download citation file:
Published: Ann Intern Med. 1999;130(6):538.
TO THE EDITOR:
The risk for venous thromboembolism in asymptomatic carriers of factor V Leiden mutation is still being debated (1). To estimate this risk, we performed a prospective cohort study in 417 family members of 64 symptomatic patients with single identified factor V Leiden mutation. All participants underwent genetic determination of this mutation and were followed for an average of 2.8 years (range, 1.8 to 3.8 years). Any clinically suspected thromboembolic episode was objectively documented with standard methods. There were 614 observation-years in 216 carriers of factor V Leiden mutation (206 heterozygous and 10 homozygous) and 583 observation-years in 201 noncarriers. The annual incidences of overall and spontaneous venous thromboembolism were 0.49% and 0.16%, respectively, in carriers and 0.34% and 0.17%, respectively, in noncarriers (relative risk, 1.4 [95% CI, 0.2 to 8.6] and 0.94 [CI, 0.1 to 15.2], respectively). These incidences did not differ from estimates available in the general population (2).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only